Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):382-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  LATEST ADVANCES IN RADIOPHARMACOLOGY AND RADIOPHARMACY 2009


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2009 August;53(4):382-5

language: English

The role of imaging in drug development

Mccarthy T. J.

Molecular Medicine, Pfizer Global Research and Development, New London, CT, USA


FULL TEXT  


The role that imaging plays as a biomarker in the discovery and development of novel therapies has grown in recent years. Imaging is now a widely used in both the preclinical and clinical stages of development, close attention is now paid to the translational relevance of imaging data in an effort to make key decisions earlier. This article describes the use of imaging as a biomarker to demonstrate proof of target, mechanism, or efficacy. Examples are provided to show the types of information that can be gathered and a sense of the size of clinical trial that is required to obtain data for each category.

top of page

Publication History

Cite this article as

Corresponding author e-mail

timothy.j.mccarthy@pfizer.com